PolyNovo Limited(CALZF)
USD --+0.00%
Reward64Moderate
Risk36Moderate
📊75%Data
Revenue growing 18% YoY
CALZF
+0.0 · +0.00%
USD · PINK
PolyNovo Limited | Healthcare
Growth Machine
Market Cap:511.22M
ℹ️
Reward Rating
64
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
36
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on CALZF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is PolyNovo Limited?

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong.

CALZF · Verdict

Solid reward · moderate risk

CALZF stands out on balance sheet and growth, but watch the valuation signal.

Based on 88% data coverage

CALZF · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet96/100

    Interest covered 32.9×

  • Growth93/100

    Revenue +45.3% CAGR

Watchouts 2

  • Valuation21/100

    P/E 34.8×

  • Volatility35/100

    Below average

Model-based scoring. For information only — not financial advice.

What is PolyNovo Limited?

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 511.22M, and a P/E ratio of 74.0x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (64)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap511.22M
P/E Ratio74
Dividend YieldN/A
52 Week High1.2
52 Week Low0.55
Last AnnualJune
IPO DateN/A
IncorporatedUSA
Shares Outstanding691M
No. of Employees301
IndustryMedical Devices
ExchangePINK
Beta1.295
CurrencyUSD · Reports in AUD